Dasatinib Accelerates Valproic Acid-Induced Acute Myeloid Leukemia Cell Death by Regulation of Differentiation Capacity

Dasatinib is a compound developed for chronic myeloid leukemia as a multi-targeted kinase inhibitor against wild-type BCR-ABL and SRC family kinases. Valproic acid (VPA) is an anti-epileptic drug that also acts as a class I histone deacetylase inhibitor. The aim of this research was to determine the...

Descripción completa

Detalles Bibliográficos
Autores principales: Heo, Sook-Kyoung, Noh, Eui-Kyu, Yoon, Dong-Joon, Jo, Jae-Cheol, Park, Jae-Hoo, Kim, Hawk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4053340/
https://www.ncbi.nlm.nih.gov/pubmed/24918603
http://dx.doi.org/10.1371/journal.pone.0098859

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4053340/
https://www.ncbi.nlm.nih.gov/pubmed/24918603
http://dx.doi.org/10.1371/journal.pone.0098859

Ejemplares similares